Drug Profile
JZP 386
Alternative Names: C-10323; Deuterated sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; Deuterium modified sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; JZP386; Sodium oxybate deuterated - Concert Pharmaceuticals/Jazz PharmaceuticalsLatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Concert Pharmaceuticals
- Developer Concert Pharmaceuticals; Jazz Pharmaceuticals plc
- Class Hydroxybutyrates; Organic deuterium compounds; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Narcolepsy
Most Recent Events
- 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
- 28 May 2019 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers) in United Kingdom (PO, Suspension)
- 30 Sep 2014 Concert Pharmaceuticals completes enrolment in its phase I trial for Narcolepsy (In volunteers) in United Kingdom before September 2014 (NCT02215499,